Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Johnson & Johnson (

3 Highest-Yielding Dividend Kings To Buy, Hold, and Forget

Discover three Dividend Kings built for buy-and-forget wealth. These stable giants may quietly deliver income and growth for decades.

Barchart

Jim Cramer Recommends These 4 Dividend Stocks, Says Era Of 'Magical Investing' In AI Is 'Dead'

CNBC host Jim Cramer has become more cautious toward AI and data center stocks after seeing increasing insider selling and borrowing activity.

Benzinga

FDA poised to kill proposal that would require asbestos testing for cosmetics

RFK Jr signed order withdrawing rule that would mandate testing for the cancer-linked toxin in talc-based makeup

The Guardian - US

From analysis to the latest developments in health,
read the most diverse news in one place.

Is Johnson & Johnson Stock Outperforming the S&P 500?

Johnson & Johnson has outpaced the S&P 500 over the past year, and analysts remain optimistic about the healthcare stock's growth potential ahead.

Barchart

What's Going On With Johnson & Johnson Stock On Wednesday?

Johnson Johnson (NYSE:JNJ) stock has surged almost 42.9% in the year to date, approximately 35% in 6 months, and 8.6% in one month.

Benzinga

Healthcare ETFs Trounce Tech, Grab Billions As Big Money Flees Bubble Fears

A powerful rotation into healthcare is taking shape across global markets, with investors pouring money into sector ETFs at one of the fastest clips this year. What started as a cautious move toward defensive stability has quickly morphed into a broader enthusiasm for biotech, pharma and healthcare-services names – helped…

Benzinga

3 Smart Defensive Stocks for an Uneasy Market

Recession risks persist despite record market highs. Here are three defensive stocks—including PG, JNJ, and the DIA ETF—that can help protect your portfolio

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

Court Rejects Bid To Block Kenvue's $398 Million Shareholder Payout In Tylenol Safety Dispute

On Friday, a Texas judge declined to halt an upcoming shareholder payout by Texas Attorney General Ken Paxton to restrict Kenvue Inc.'s (NYSE:KVUE) handling and marketing of Tylenol amid ongoing litigation over the product's safety for pregnant women.

Benzinga

3 High-Growth Dividend Kings For Generations of Income - And Still Rated “Buy”

Dividend Kings with 20%+ YTD gains and strong analyst ratings show rare momentum, reliable income, and long-term stability across multiple sectors.

Barchart

The innovative new treatment which could help cancer patients avoid surgery

Bladder cancer is the ninth most common cancer in the world, the fourth most common cancer in men, and the 11th most common cancer in women

The Independent UK

FDA Clears Johnson & Johnson's Darzalex Faspro, Enabling Early Intervention In Myeloma Progression

The U.S. Food and Drug Administration (FDA) approved on Thursday Johnson Johnson’s (NYSE:JNJ) Darzalex Faspro (daratumumab and hyaluronidase-fihj) for a type of blood cancer.

Benzinga

Kimberly-Clark Snaps Up Tylenol Maker Kenvue in £30 Billion Takeover Amid Autism Controversy

Kimberly-Clark to acquire Kenvue, owner of Tylenol, in a £40 billion deal amid controversy over the painkiller's safety concerns and declining sales.

International Business Times UK

Kenvue Acquired by Kimberly-Clark in $48.7 Billion Deal to Form Consumer Staples Giant

Kimberly-Clark will acquire Kenvue in a $48.7 billion cash-and-stock deal, creating a new consumer health and personal care giant combining brands like Huggies, Kleenex, Johnson's Baby, and Band-Aid.

International Business Times UK

Johnson & Johnson Stock: Is Wall Street Bullish or Bearish?

Johnson & Johnson has delivered a standout performance in 2025, outperforming both the broader market and the healthcare sector. Analysts continue to be fairly bullish on the stock’s trajectory.

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

The Only 3 Dividend Kings You’ll Ever Need for a Lifetime of Income

Three Dividend Kings with decades of dividend growth and strong financials are poised to deliver reliable income and stability for investors in 2025.

International Business Times UK

Texas Sues Johnson & Johnson for 'Hiding' Tylenol Autism Risks — Billions at Stake in Landmark Case

Texas sues Tylenol's makers over autism risks, echoing Trump-era legal battles over health misinformation with potential billions at stake.

The Guardian - US

Texas sues Tylenol makers alleging deceptive marketing to pregnant people

Lawsuit comes after Trump’s baseless claims that acetaminophen can cause autism and ADHD in children

Benzinga

Ken Paxton Alleges Johnson & Johnson Misled Mothers On Tylenol Safety

Texas Attorney General Ken Paxton has filed a lawsuit against Johnson Johnson (NYSE:JNJ) and Kenvue Inc (NYSE:KVUE), accusing the companies of misleading pregnant women about the safety of Tylenol despite evidence suggesting its active ingredient, acetaminophen, may increase the risk of autism and attention disorders in children.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Texas lawsuit against companies behind Tylenol asserts unproven claims of autism risk

Texas Attorney General Ken Paxton is accusing the companies behind Tylenol of deceptively marketing the pain reliever to pregnant mothers

International Business Times UK

Texas Attorney General Targets Tylenol Makers in Controversial Autism Lawsuit

Texas Attorney General Ken Paxton sues Johnson & Johnson and Kenvue, alleging they hid risks linking prenatal Tylenol use to autism and ADHD in children.

The Independent UK

Texas sues Tylenol makers over RFK Jr autism claims saying they failed to state ‘risk of taking drug while pregnant’

State Attorney General Ken Paxton parroted claims by the Health Secretary which have been strongly refuted by medical professionals

Barchart

Tylenol-Maker Kenvue’s Stock Is Down 30% in 2025. Its Fate May Be in the FDA’s Hands.

The former consumer health unit of Johnson & Johnson remains mired in troubles surrounding Tylenol.

Barchart

5 Safe Income Stocks Still Worth Owning

These companies have maintained their records of paying and increasing dividends.

MarketBeat

Johnson & Johnson's M&A Strategy Is the Real Story for Investors

Johnson & Johnson’s rumored Protagonist buyout demonstrates its proven M&A strategy: divesting low-growth units to fund high-margin, innovative assets.

Evening Standard

Johnson & Johnson lawsuit explained: Families sue over baby powder cancer claims

Thousands in the UK are suing Johnson & Johnson, alleging that the company's baby powder products concealed cancer risks

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.